Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023

ウイルスベクター製造の世界市場予測(~2023年):レトロウイルス、ガンマレトロウイルス、AAV

◆タイトル:Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023
◆商品コード:BT-6497
◆調査・発行会社:MarketsandMarkets
◆発行日:2018年8月2日
◆ページ数:149
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:
◆産業分野:バイオテクノロジー
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、ウイルスベクター製造の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別(レトロウイルス、ガンマレトロウイルス、AAV)分析、疾患別(がん、感染症、遺伝性疾患)分析、用途別(遺伝子治療、ワクチン)分析、エンドユーザー別(バイオテクノロジー企業、研究機関)分析、ウイルスベクター製造の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global viral vector manufacturing market is projected to reach USD 815.8 million by 2023 from USD 327.8 million in 2018, at a CAGR of 20.0%. Some key factors driving market growth include the rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. Untapped potential in emerging markets is expected to offer lucrative growth opportunities for players in the market.
In this report, the global market is segmented by type, disease, application, end user. By type, the market is segmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. The adeno-associated viral vector manufacturing segment is expected to grow at the highest CAGR during the forecast period as they have applications in most cell-based gene therapies.

Based on disease, the market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. In 2018, cancer is expected to account for the largest share of the global market. Its large share can be attributed to growing research on viral vector gene therapies for cancer.

By application, the viral vector manufacturing market is segmented into gene therapy and vaccinology. The gene therapy segment is expected to grow at the highest rate during the forecast period. The availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research activities on viral vector gene therapies, and the recent approval of several viral vector gene therapies are driving the growth of this market.

Based on end users, the viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research institutes. In 2018, pharmaceutical and biopharmaceutical companies are expected to account for the largest share of the global market. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the pharmaceutical and biopharmaceutical companies segment during the forecast period.

Viral Vector Manufacturing Market

Geographically, Asia Pacific is expected to grow at the fastest rate viral vector manufacturing market during the forecast period. The fast growth of this regional segment can be attributed to the growing research activities to launch novel gene therapies in the untapped markets of this region.

While the overall market is expected to grow during the forecast period, the high price of gene therapies and short shelf-life of viral vectors are likely to restrain the growth of this market to a certain extent. The major players in the global market include Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).

【レポートの目次】

1 Introduction (Page No. – 11)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Stakeholders

2 Research Methodology (Page No. – 14)
2.1 Primary Data
2.1.1 Key Data From Primary Sources
2.1.2 Key Industry Insights
2.2 Secondary Data
2.2.1 Key Data From Secondary Sources
2.3 Market Size Estimation
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 22)

4 Premium Insights (Page No. – 24)
4.1 Market Overview

5 Market Overview (Page No. – 25)
5.1 Introduction
5.2 Evolution
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
5.3.1.2 Availability of Funding for the Development of Gene Therapy
5.3.1.3 Effectiveness of Viral Vectors
5.3.1.4 Ongoing Research Into Viral Vector-Based Gene and Cell Therapies
5.3.2 Restraints
5.3.2.1 High Costs Associated With Gene Therapy
5.3.2.2 Short Shelf-Life of Viral Vectors
5.3.3 Challenges
5.3.3.1 Risk of Mutagenesis and Other Unwanted Outcomes

6 Viral Vector Manufacturing Market, By Type (Page No. – 31)
6.1 Introduction
6.2 Retroviral Vectors
6.2.1 Lentiviral Vectors
6.2.2 Gamma-Retroviral Vectors
6.3 Adenoviral Vectors
6.4 Adeno-Associated Viral Vectors
6.5 Other Viral Vectors

7 Viral Vector Manufacturing Market, By Disease (Page No. – 40)
7.1 Introduction
7.2 Cancer
7.3 Genetic Disorders
7.4 Infectious Diseases
7.5 Other Diseases

8 Viral Vector Manufacturing Market, By Application (Page No. – 47)
8.1 Introduction
8.2 Gene Therapy
8.3 Vaccinology

9 Viral Vector Manufacturing Market, By End User (Page No. – 51)
9.1 Introduction
9.2 Pharmaceutical and Biopharmaceutical Companies
9.3 Research Institutes

10 Viral Vector Manufacturing Market, By Region (Page No. – 55)
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 Rest of the World

11 Competitive Landscape (Page No. – 68)
11.1 Overview
11.1.1 Product Approval
11.1.2 Collaborations, Partnerships, and Agreements
11.1.3 Acquisitions and Mergers
11.1.4 Expansions

12 Company Profiles (Page No. – 71)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 Lonza
12.2 Merck KGaA
12.3 Oxford Biomedica
12.4 Cobra Biologics
12.5 Novasep
12.6 Spark Therapeutics
12.7 Kaneka Eurogentec
12.8 Finvector Vision Therapies
12.9 Brammer Bio
12.10 Cell and Gene Therapy Catapult (CGT Catapult)
12.11 Fujifilm Holdings Corporation
12.12 Uniqure
12.13 Regenxbio
12.14 Massbiologics

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 99)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details

List of Tables (50 Tables)

Table 1 Approved Viral Vector Gene Therapies
Table 2 Number of Clinical Trials Registered on Various Viral Vectors Globally
Table 3 Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 4 Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 5 Market for Retroviral Vectors, By Region, 2016–2023 (USD Million)
Table 6 Market for Lentiviral Vectors, By Region, 2016–2023 (USD Million)
Table 7 Viral Vector Manufacturing Market for Gamma-Retroviral Vectors, By Region, 2016–2023 (USD Million)
Table 8 Market for Adenoviral Vectors, By Region, 2016–2023 (USD Million)
Table 9 Viral Vector Manufacturing Market for Adeno-Associated Viral Vectors, By Region, 2016–2023 (USD Million)
Table 10 Gene Therapy Applications of Other Viral Vectors
Table 11 Market for Other Viral Vectors, By Region, 2016–2023 (USD Million)
Table 12 Viral Vector Manufacturing Market, By Disease, 2016–2023 (USD Million)
Table 13 Market for Cancer, By Region, 2016–2023 (USD Million)
Table 14 Phase Iii/Iv Clinical Trials Based on Monogenic Diseases
Table 15 Market for Genetic Disorders, By Region, 2016–2023 (USD Million)
Table 16 Viral Vector Manufacturing Market for Infectious Diseases, By Region, 2016–2023 (USD Million)
Table 17 Market for Other Diseases, By Region, 2016–2023 (USD Million)
Table 18 Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 19 Market for Gene Therapy, By Region, 2016–2023 (USD Million)
Table 20 Viral Vector Vaccines Pipeline
Table 21 Viral Vector Manufacturing Market for Vaccinology, By Region, 2016–2023 (USD Million)
Table 22 Market, By End User, 2016–2023 (USD Million)
Table 23 Market for Pharmaceutical and Biopharmaceutical Companies, By Region, 2016–2023 (USD Million)
Table 24 Viral Vector Manufacturing Market Size for Academic Research Institutes, By Region, 2016–2023 (USD Million)
Table 25 Market, By Region, 2016–2023 (USD Million)
Table 26 North America: Market, By Type, 2016–2023 (USD Million)
Table 27 North America: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 28 North America: Viral Vector Manufacturing Market, By Disease, 2016–2023 (USD Million)
Table 29 North America: Market, By Application, 2016–2023 (USD Million)
Table 30 North America: Viral Vector Manufacturing Market, By End User, 2016–2023 (USD Million)
Table 31 Europe: Market, By Type, 2016–2023 (USD Million)
Table 32 Europe: Viral Vector Manufacturing Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 33 Europe: Market, By Disease, 2016–2023 (USD Million)
Table 34 Europe: Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 35 Europe: Market, By End User, 2016–2023 (USD Million)
Table 36 APAC: Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 37 APAC: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 38 APAC: Market, By Disease, 2016–2023 (USD Million)
Table 39 APAC: Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 40 APAC: Market, By End User, 2016–2023 (USD Million)
Table 41 RoW: Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 42 RoW: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 43 RoW: Market, By Disease, 2016–2023 (USD Million)
Table 44 RoW: Market, By Application, 2016–2023 (USD Million)
Table 45 RoW: Market, By End User, 2016–2023 (USD Million)
Table 46 Rank of Companies in the Global Viral Vector Market, 2018
Table 47 New Approval , 2015–2018
Table 48 Agreements, Partnerships and Collaborations, 2015–2018
Table 49 Acquisitions 2015-2018
Table 50 Expansions, 2015–2018

List of Figures (22 Figures)

Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Retroviral Vectors Dominate the Vira Vectors Manufacturing Market
Figure 7 Geographical Snapshot: High Growth Expected in Emerging APAC Markets During the Forecast Period
Figure 8 Accelerated Research Activities in Gene Therapy Drive the Market
Figure 9 Cancer to Dominate the Viral Vectors Manufacturing Market By Disease (2018)
Figure 10 Timeline for Major Events in Gene Therapy
Figure 11 Viral Vectors Manufacturing Market: Drivers, Restraints, and Challenges
Figure 12 Adeno-Associated Viral Vectors: Targeted Therapies
Figure 13 Gene Therapy Research Targets
Figure 14 Number of Gene Therapies in Various Clinical Trial Phases
Figure 15 Lonza: Company Snapshot
Figure 16 Merck KGaA: Company Snapshot
Figure 17 Oxford Biomedica: Company Snapshot
Figure 18 Spark Therapeutics: Company Snapshot
Figure 19 Kaneka Corporation: Company Snapshot (2017)
Figure 20 Fujifilm Holdings Corporation: Company Snapshot (2017)
Figure 21 Uniqure: Company Snapshot (2017)
Figure 22 Regenxbio: Company Snapshot (2017)



★調査レポート[ウイルスベクター製造の世界市場予測(~2023年):レトロウイルス、ガンマレトロウイルス、AAV] ( Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023 / BT-6497) 販売に関する免責事項
[ウイルスベクター製造の世界市場予測(~2023年):レトロウイルス、ガンマレトロウイルス、AAV] ( Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023 / BT-6497) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆